Table 2 Demographic and clinical characteristics between MDD patients with and without anxiety symptoms, grouped by gender
Variables | With anxiety (N = 138) | Without anxiety (N = 656) | Gender F (p) | Subgroup F (p) | Gender* subgroup F (p) | ||
|---|---|---|---|---|---|---|---|
Male | Female | Male | Female | ||||
Sample size | 38 | 100 | 201 | 455 | |||
Age (years) | 38.53 ± 11.35 | 38.58 ± 12.85 | 35.35 ± 12.72 | 38.13 ± 12.59 | 1.15 (0.28) | 1.89 (0.16) | 1.06 (0.30) |
Duration of disease (months) | 9.03 ± 5.81 | 7.13 ± 4.43 | 6.84 ± 5.43 | 6.71 ± 4.64 | 3.95 (0.04) | 6.48 (0.01) | 3.02 (0.08) |
Age of onset (years) | 38.15 ± 11.16 | 38.34 ± 12.71 | 35.10 ± 12.54 | 37.90 ± 12.49 | 1.31 (0.25) | 1.79 (0.18) | 1.01 (0.31) |
HAMD | 34.53 ± 2.41 | 33.65 ± 2.43 | 30.73 ± 2.54 | 30.62 ± 2.63 | 3.31 (0.06) | 161.06 (0.00) | 2.07 (0.15) |
HAMA | 27.21 ± 1.64 | 27.42 ± 2.07 | 20.31 ± 2.58 | 20.26 ± 2.63 | 0.090(0.76) | 715.49 (0.00) | 0.24 (0.61) |
TSH, µIU/L | 7.74 ± 2.11 | 8.47 ± 2.36 | 5.98 ± 2.35 | 5.95 ± 2.37 | 2.05 (0.15) | 75.60 (0.00) | 2.37 (0.12) |
TgAb, IU/L | 163.55 ± 371.05 | 160.78 ± 324.47 | 87.48 ± 200.23 | 100.45 ± 235.48 | 0.03 (0.84) | 6.93 (0.01) | 0.09 (0.76) |
TPOAb, IU/L | 203.17 ± 350.12 | 134.79 ± 262.49 | 77.76 ± 150.90 | 90.35 ± 196.84 | 1.68 (0.19) | 15.64 (0.00) | 3.55 (0.06) |
FT3, pmol/L | 4.90 ± 0.84 | 4.91 ± 0.70 | 4.97 ± 0.69 | 4.89 ± 0.70 | 0.20 (0.60) | 0.11 (0.73) | 0.38 (0.53) |
FT4, pmol/L | 17.45 ± 2.86 | 16.78 ± 3.02 | 16.60 ± 3.14 | 16.50 ± 3.09 | 1.42 (0.23) | 3.09 (0.07) | 0.76 (0.38) |